Trastuzumab is the standard <i>HER2</i>-targeted therapy for <i>HER2+</i> breast cancers in the adjuvant setting, and is increasingly being used as a neoadjuvant chemotherapy treatment (NACT or NAC). Here, ERBB2 is linked to breast cancer.